Ovid Therapeutics (OVID) 10-Q2024 Q3 Quarterly report

Filed: 12 Nov 24, 8:07am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: ACH, aminotransferase, anticonvulsant, blocked, Bureau, cell, clearance, Committee, conference, contact, continuum, contrast, costlier, cyber, dysfunction, dysregulation, email, emphasize, enrichment, Epilepsy, extrasynaptic, eye, fairly, fifteen, frozen, GABA, identification, impersonating, interdict, intramuscular, irrevocable, led, light, mechanistic, mechanistically, mice, military, misdirection, neurodegenerative, neurodevelopmental, neuroinflammation, neuropsychiatric, neurovascular, noncash, OFAC, older, optimize, oral, pharmacokinetic, plasma, potent, promptly, rapid, rapidly, recovery, remitted, retina, retinal, sedation, signal, skepticism, Society, spear, suggesting, synaptic, tissue, tolerability, unaddressed, undisclosed, unmet, upcoming, vascular, vendor, victim, violence, wire

Removed: activation, acute, built, clinic, concrete, EEG, electroencephalogram, extrinsic, field, formulated, guided, intractable, intrinsic, leader, leverage, marker, measurable, neurologic, progressed, progressing, refractory, shared, transform

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

OVID similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Jeremy M. Levin, Chief Executive Officer of Ovid Therapeutics Inc. (the “Company”), and Jeffrey Rona, Chief Business and Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 12, 2024


/s/ Jeremy M. Levin						/s/ Jeffrey Rona
Jeremy M. Levin						Jeffrey Rona
Chief Executive Officer (Principal Executive Officer)						Chief Business and Financial Officer (Principal Financial and Accounting Officer)